BACH1 Pathway Metastasis Signature for Triple Negative Breast Cancer

SUMMARY

• Triple negative breast cancer (TNBC) patients are a clinically underserved group, with fewer therapy options available compared to other breast cancer patients and poorer survival statistics. Current breast cancer diagnostics are limited in resolution with TNBC patients, and as such, clinicians need additional tools to evaluate them.
• The inventors identified 30 genes that are downstream of the metastasis regulator, BACH1. These genes can stratify patients with the most lethal forms of TNBC.
• The invention is a prognostic gene signature for predicting relapse free survival in TNBC breast cancer patients. This gene signature can be used with pre-existing diagnostic kits to boost the resolution of patient stratification.
• The gene signature was validated in a retrospective cohort (n=1600) of breast cancer patients. 10-20% of patients predicted to have good prognosis by FDA approved diagnostics were shown to have poor prognosis by the BACH1 supplemental gene signature.

FIGURE

ADVANTAGES

ADVANTAGES

• Further patient stratification over existing signatures
• Specific to TNBC patients

APPLICATIONS

• Oncology precision medicine
• Clinical trial enrollment

PUBLICATIONS

• Lee, U; et al. A prognostic gene signature for metastasis-free survival of triple negative breast cancer patients. PLoS One. 2013 Dec 11;8(12):e82125.

August 2, 2019

Clinical (retrospective dataset)

Patent Pending

Licensing

Marsha Rosner

• US: 14/952,265